NDAORALTABLET
Approved
Aug 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Orexin Receptor Antagonists
Pharmacologic Class:
Orexin Receptor Antagonist
Clinical Trials (5)
A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)
Started Oct 2025
300 enrolled
Insomnia
Suvorexant for Treatment of AUD and PTSD
Started Jul 2025
76 enrolled
Alcohol Use Disorder (AUD)Post Traumatic Stress Disorder (PTSD)Insomnia
Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors
Started Sep 2024
5 enrolled
Breast CancerInsomnia
REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant
Started Jun 2023
142 enrolled
Delirium in Old Age
Efficacy of Suvorexant on Post-operative Sleep Disturbance
Started May 2023
92 enrolled
Postoperative InsomniaPostoperative Delirium
Loss of Exclusivity
LOE Date
May 29, 2033
88 months away
Patent Expiry
May 29, 2033